These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30451732)

  • 1. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
    Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
    Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
    Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
    Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
    Stenman A; Zedenius J; Juhlin CC
    Langenbecks Arch Surg; 2018 Sep; 403(6):785-790. PubMed ID: 29779047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A; Zedenius J; Juhlin CC
    Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
    Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
    PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature.
    Stenman A; Zedenius J; Juhlin CC
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30769931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
    Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
    Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
    Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
    J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
    Juhlin CC
    Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.
    Thompson LD
    Am J Surg Pathol; 2002 May; 26(5):551-66. PubMed ID: 11979086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
    Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
    J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
    Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
    Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
    J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical Expression of Choline Acetyltransferase and Catecholamine-Synthesizing Enzymes in Head-and-Neck and Thoracoabdominal Paragangliomas and Pheochromocytomas.
    Kimura N; Shiga K; Kaneko KI; Oki Y; Sugisawa C; Saito J; Tawara S; Akahori H; Sogabe S; Yamashita T; Takekoshi K; Naruse M; Katabami T
    Endocr Pathol; 2021 Dec; 32(4):442-451. PubMed ID: 34743284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.
    Pang LC; Tsao KC
    Arch Pathol Lab Med; 1993 Nov; 117(11):1142-7. PubMed ID: 8239937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the management of pheochromocytoma and paraganglioma.
    Tanabe A; Naruse M
    Hypertens Res; 2020 Nov; 43(11):1141-1151. PubMed ID: 32778780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.